Truist Securities Initiates Coverage On Y-mAbs Therapeutics with Buy Rating, Announces Price Target of $21
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has initiated coverage on Y-mAbs Therapeutics (NASDAQ:YMAB) with a Buy rating and set a price target of $21.
June 28, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has initiated coverage on Y-mAbs Therapeutics with a Buy rating and set a price target of $21.
The initiation of coverage with a Buy rating and a specific price target of $21 by Truist Securities is likely to positively impact the stock price of Y-mAbs Therapeutics in the short term. Analyst ratings and price targets are significant indicators for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100